Physician profile
Mark J Reddan
NPI 1558390229
$3,358.11
in general payments reported to CMS, 2019-2025
19 companies · $863 in 2025
The $863 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $172 · 2021: $236 · 2022: $312 · 2023: $534 · 2024: $819 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $858.18 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Abbvie INC. | $471.56 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $429.10 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $296.14 | 2019-2025 | Rocklatan, Clareon, Total30 |
| Sun Pharmaceutical Industries INC. | $289.08 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.27 | 2019-2021 | |
| Allergan, INC. | $201.60 | 2019-2021 | |
| Thea Pharma INC. | $108.24 | 2023-2025 | Iyuzeh |
| Coopervision INC. | $105.75 | 2022-2025 | Clariti Contact Lens, Myday Contact Lens |
| Dompe US, INC. | $86.61 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $81.22 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $51.30 | 2019-2024 | Acuvue |
| Aerie Pharmaceuticals, INC. | $36.13 | 2020-2021 | |
| Biotissue Holdings INC. | $32.46 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $30.92 | 2025 | Clarus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20.63 | 2019 | |
| Amgen INC. | $17.38 | 2025 | Tepezza |
| Glaukos Corporation | $17.23 | 2019 | |
| Harrow Eye, LLC | $16.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Reddan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.